HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

Semaglutide's 3.1-year biological age reversal rests on one DNA clock

Louis Nervegna · Nov 11, 2026 · ♥ 1 reactions · 0 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Aging & longevity
AI summary & key facts

Louis shares a podcast summary examining whether semaglutide slows aging. The 2025 claim of a 3.1-year biological age reversal came from a single DNA aging clock over 32 weeks scaled up. LEADER, SELECT and FLOW showed real reductions in heart events and deaths, evoke trials showed no Alzheimer's slowing, and old female mice lived about 12% longer.

#glp1HD #glp1agingHD #agingHD #longevityHD #leaderHD #selectHD #flowHD

Research cited

In 2025, a company claimed semaglutide reversed biological age by 3.1 years. Is that real?

It started with lizard venom at the Bronx VA in 1992 and moved through Novo Nordisk's albumin trick to Ozempic in 2017.

The outcome trials like LEADER, SELECT and FLOW showed real drops in heart events and deaths.

The 3.1-year number came from a single DNA aging clock measured over 32 weeks and scaled up to a yearly rate. The evoke Alzheimer's trials didn't slow decline. A 2026 study found older female mice on semaglutide lived about 12% longer.

Semaglutide clearly lowers the risk of the diseases that shorten lives. Whether it slows human aging is still open.

Full episode is up on YouTube

May be an image of one or more people, beard and textMay be an image of textMay be an image of textMay be an image of textMay be an image of text
← newer: CoQ10 curbed Alzheimer's-like damage spread in mice; human Colder: Linoleic acid (omega-6) improves insulin sensitivity via PPA →